Member Info for JPP8788

I was shot down in flames by a few when I originally suggested the connection almost a month ago.. And repeatedly since..

It seems that now, more than ever, we are edging closer to a positive outcome. This is as pleased as I've ever been to be holding many millions of this stock.

Best wishes to all.

@DCR..

Thanks for the information..

What sorts of news will those documents give us, do you think? How the equity will be split? Whether we will IPO or list through a shell?

Basically BOU can be used as a vehicle to list Accustem on the London main exchange, much quicker and cheaper than it would be through an IPO. Tiziana will also take any remaining cash from BOU, and also get the services of Allan Syms.

I suspect the next update we are looking for is Tizianas AGM to check the special resolutions required...

So an IPO can take 3-6 months.

A reverse takeover (RTO) can be completed in 2 weeks.

Looks ever more likely to be a cash shell listing given the timescales we think we're working towards (the end of July)

Thanks for relying oldapache - I'm fairly new to this game (only trading 18 months or so) but ultimately I've learnt to be cautious rather than optimistic.. Saves disappointment that way!

My 2/3x takeover of a 150m mcap was based on my own feelings and thoughts... If its anymore than that then I'd be absolutely made up. I'm a LTH here.. Traded out from the early days of 40p a share and now bought back in the 90s for the longer term.

GL.

See - there's far too much of this...

Just because Oncotype DX was sold for whatever amount.. That doesn't automatically mean accustem is worth more as business.

StemPrintER is not that close to commercialisation. It will need LOTS of funding and time to get to that stage.

I would think that Accustem will launch on the market at a 50-150 million mcap and probably then be fairly quickly bought out for 2/3x that

Sorry - following on from below...

They sold EmaCo AG to Sobi.. Not Sanofi...?

I wonder if that's what you confused with?

Novimmune have recently rebranded as Light Chain Bioscience.. They did so after they sold demerged their emapalumab into a separate company (EmaCo AG) for around £430m

The general consensus is that Accustem will launch with a reasonably small mcap (I would guess 50-100 Mill), but then be subject to an early takeover or acquisition from a major pharma to get the product commercialised.

After all this time... I would have imagine that I would taken my loot and ran when BOU relisted... But now.... No... I'm looking at the longer term plan!

Been doing some number crunching this morning... I reckon if it costs tiziana 20-30% of their share price (at the time of demerger) to launch and fund accustem.... And then accustem hits the market with a 150 million mcap... You'll have approximately doubled your money from here

And 150 million mcap is certainly viable.

Looks as if Tiziana have created a subsidiary called "Accustem Sciences Ltd"... This company was incorporated about 1 week ago. Clearly that is the vehicle for listing StemPrintER.

Having seen this news I now feel a little foolish - but it doesn't actually stop a potential RTO? I guess that Accustem will now need to start quite a lengthy process to gain main market listing... Maybe we are still related after all?

Now postponed due to originally Covid (and their subsequent treatment drug) and now StemPrintER - nasdaq is 5 to 1 shares in issue so the majority of the business is done over there.. I suspect getting StemPrintER span out and sold off is currently priority. Then it may well cease trading on AIM (but you'll end up with nasdaq shares)

We many only end up with a small percentage of the new company - but I, like most on this bb, would be happy with anything at this stage. I don't see StemPrintER listing with less than a £100-200 million mcap upon listing, and from there the sky is the limit.

I've seen a few messages on this board asking why TILS would benefit from BOU - here's my answer...

We know that Bould cannot relist on AIM, but can relist on a "recognised stock exchange". We also know that AG has warrants that can only be exercised on a UK market. Therefore it is wholly in BOU's interest to relist on the London Main Market. This is probably obvious to many...

But what benefit for TILS? Well.. A main market listing costs just under 1 million pounds, and is exceptionally time consuming. We saw the RNS from TILS this week with an ATM extension until the end of July. For anyone who is unsure, an ATM is to raise cash and liquidity ahead of (usually) a major project. So the demerger looks certain to be happening before then. This doesn't allow TILS enough time to apply for a main market listing - if they want a listing quickly (potentially for a quick buy out), then a cash shell absolutely works. The money saved from a main market listing (combined with whatever little cash BOU still have) is of benefit to TILS as an immediate cash saving. Which CEO would NOT want to save circa 1 million pounds?

TILS are likely to prefer a main market listing over AIM - the extra security and general confidence it gives potential investors is likely to be very valuable. But you must have a market cap of 700k minimum to become a main market listing... Would LSE approve a listing that is currently none-revenue generating? Clearly the value of StemPrintER and SPARE is based on its projections over the coming years - very enticing to a big pharma company or similar!

If TILS were to look towards AIM as a vehicle to list StemPrintER, then it appear to me that all investors who hold more then 0.5% of the shares in issue are locked in for 1 year and cannot sell. This is due to the fact that the spin off company have not been earning any revenue for 24 months. Doesn't sound very good news for either new or existing large shareholder, does it?

A NOMAD is NOT required on the main market but is through AIM. More cost saving for Cerrone.

And if course, as Cerrone said in his interview with Proactive Investors on 22nd May - "(StemPrintER) will have a more specialised expertise in the genomics field running the newco". I think the fact that Allan Syms is just about as "specialised" as you're going to get is a major boon for TILS and STEM. Just "Allan Syms Genomics" for yourself and see... The guy is a leader in the field. Cerrone gets Syms and very quick main market listing for "free", we get StemPrintER, Antos can exercise his warrants and make off with a small fortune (and the Halcyon technology and rights) and everyone is happy.

Now feel free to tell me that I'm dreaming, or if something I've said doesn't add up or make sense. Just remember - oncotypeDX sold to exact sciences 7 months ago for 2.8 billion. This is far, far inferior to StemPrintER. Of course our holdings will be diluted - we many only end

Cerrone wants a listing on a "London Exchange". We don't know what BOU have been doing in the background.. But an obvious lack of interest in an AIM extension speaks volumes. This is going onto LSE quite clearly.

The link between the update RNS from Bould citing a biotechnology acquisition for a patent portfolio (StemPrintER and SPARE) involved in early detection of a specific cancer which is proven to increase five year survival rates..

Bould have been "working for some time" on this acquisition... And if you look at Tizianas RNS that announces the StemPrintER spin out... It says "the board has been considering options for StemPrintER for some time".

Like I've said before.

May be just a massive coincidence, and I'm fine with that.

But I still firmly believe.

Appreciate your reply CC. -

We can only wait. I have more research and info than I've posted here - I too am aware of the implications of unveiling market info too early.. So I'll leave it here for now.

Good luck all.

Frustrated like many others.

But still firmly and strongly believe BOU is involved in the spin out of StemPrintER from Tiziana.

Too many coincidences.

Very interesting.

Looks like AG has got the rights and all the patents related to all of Photonstars business.

Clearly beneficial to him and his new venture.

But he has warrants here also - I personally think AG wanted a BOGOF. Rights to Photonstar and all of the related IP... And a return on investment in the form of an RTO... and he's not far from getting it.

Now showing as reversed on LSE?

What the hell?

So let me get this straight...

Someone has bought 5 million pounds worth of shares at 22p

Presumably the only price they could get from the MMs given the scale?

So then, why would you want to buy that much so quickly? Imminent takeover bid? That's the only thing I can think of?

Otherwise why not stagger 1 million over 5 days?